COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom. Show more

33 Broadwick Street, London, W1F 0DQ, United Kingdom

Medical Care Facilities

Healthcare

Start AI Chat

Market Cap

753.7M

52 Wk Range

$2.25 - $8.90

Previous Close

$7.85

Open

$7.90

Volume

2,700,372

Day Range

$7.63 - $8.03

Enterprise Value

390M

Cash

185.9M

Avg Qtr Burn

-35.11M

Insider Ownership

9.36%

Institutional Own.

52.81%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
COMP360 (Psilocybin) Details Treatment Resistant Depression	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COMP360 (Psilocybin) Details Post-traumatic stress disorder	Phase 2/3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COMP360 (Psilocybin) Details Anorexia nervosa	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.